PMID- 25725314
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20171116
IS  - 1872-9142 (Electronic)
IS  - 0161-5890 (Linking)
VI  - 65
IP  - 2
DP  - 2015 Jun
TI  - Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial 
      cells of patients on peritoneal dialysis therapy.
PG  - 302-9
LID - S0161-5890(15)00045-0 [pii]
LID - 10.1016/j.molimm.2015.02.005 [doi]
AB  - We investigated the expression of membrane complement regulators (CRegs), CD46, 
      CD55 and CD59 in human mesothelial cells, and correlated with clinical background 
      and level of complement (C) activation products in peritoneal dialysis (PD) 
      fluids (PDF) to clarify influence of the C activation system in PD patients. 
      Expression of CRegs was assessed on primary cultures of mesothelial cells (HPMC) 
      harvested from PD fluid of 31 PD patients. Because expression of CD55 but not 
      CD46 and CD59 in mesothelial cells was significantly correlated to value of 
      dialysate-to-plasma creatinine concentration ratio (D/P Cre) (p<0.005) as an 
      indicator of peritoneal function, we focused on analysis of CD55 expression of 
      HPMCs in comparison with levels of C activation products in the PDF of the PD 
      patients, and their background factors. When comparing expression of the CRegs 
      between systemic neutrophils and HPMC, no correlation was observed, supporting 
      that change of CRegs' expression in HPMC was independently occurring in the 
      peritoneum. Expression of CD55 protein in HPMC was closely correlated with 
      expression at the mRNA level (p<0.0001) and was inversely correlated with levels 
      of sC5b-9 (p<0.05), but not C3, C4, IL6 and CA125 in the PDF. Complications of 
      diabetes, usage of icodextrin and residual renal function were not correlated 
      with change of CD55 expression in HPMCs. Our data show that the process of PD 
      therapy modifies expression of CD55 on peritoneal mesothelium and triggers local 
      C activation. These findings support efforts to modify PD therapy to limit 
      effects on activation and regulation of the C system.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Sei, Yumi
AU  - Sei Y
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Mizuno, Masashi
AU  - Mizuno M
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan; Renal Replacement Therapy, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan. Electronic address: mmizu@med.nagoya-u.ac.jp.
FAU - Suzuki, Yasuhiro
AU  - Suzuki Y
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan; Renal Replacement Therapy, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Imai, Masaki
AU  - Imai M
AD  - Immunology, Nagoya City University Graduate School of Medicine, Nagoya, Japan.
FAU - Higashide, Keiko
AU  - Higashide K
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Harris, Claire L
AU  - Harris CL
AD  - Complement Biology Group, Institute of Infection and Immunity, School of 
      Medicine, Cardiff University, Cardiff, UK.
FAU - Sakata, Fumiko
AU  - Sakata F
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan; Renal Replacement Therapy, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
FAU - Iguchi, Daiki
AU  - Iguchi D
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Fujiwara, Michitaka
AU  - Fujiwara M
AD  - Department of Gastroenterological Surgery (Surgery II), Nagoya University 
      Graduate School of Medicine, Nagoya, Japan.
FAU - Kodera, Yasuhiro
AU  - Kodera Y
AD  - Department of Gastroenterological Surgery (Surgery II), Nagoya University 
      Graduate School of Medicine, Nagoya, Japan.
FAU - Maruyama, Shoichi
AU  - Maruyama S
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Matsuo, Seiichi
AU  - Matsuo S
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Ito, Yasuhiko
AU  - Ito Y
AD  - Division of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan; Renal Replacement Therapy, Nagoya University Graduate School of Medicine, 
      Nagoya, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150225
PL  - England
TA  - Mol Immunol
JT  - Molecular immunology
JID - 7905289
RN  - 0 (CA-125 Antigen)
RN  - 0 (CD46 protein, human)
RN  - 0 (CD56 Antigen)
RN  - 0 (CD59 Antigens)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (MUC16 protein, human)
RN  - 0 (Membrane Cofactor Protein)
RN  - 0 (Membrane Proteins)
RN  - 0 (NCAM1 protein, human)
RN  - 101754-01-2 (CD59 protein, human)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - CA-125 Antigen/immunology
MH  - CD56 Antigen/*immunology
MH  - CD59 Antigens/*immunology
MH  - Complement Activation
MH  - Complement System Proteins/immunology
MH  - Epithelial Cells/*immunology/pathology
MH  - Epithelium/immunology/pathology
MH  - Female
MH  - Gene Expression Regulation/*immunology
MH  - Humans
MH  - Interleukin-6/immunology
MH  - Male
MH  - Membrane Cofactor Protein/*immunology
MH  - Membrane Proteins/immunology
MH  - *Peritoneal Dialysis
OTO - NOTNLM
OT  - CD55
OT  - Complement
OT  - D/P creatinine
OT  - Membrane complement regulators
OT  - Peritoneal dialysis
EDAT- 2015/03/01 06:00
MHDA- 2015/05/12 06:00
CRDT- 2015/03/01 06:00
PHST- 2014/10/21 00:00 [received]
PHST- 2015/01/31 00:00 [revised]
PHST- 2015/02/05 00:00 [accepted]
PHST- 2015/03/01 06:00 [entrez]
PHST- 2015/03/01 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - S0161-5890(15)00045-0 [pii]
AID - 10.1016/j.molimm.2015.02.005 [doi]
PST - ppublish
SO  - Mol Immunol. 2015 Jun;65(2):302-9. doi: 10.1016/j.molimm.2015.02.005. Epub 2015 
      Feb 25.